drugset / Trial / NCT07233239
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
Phase 1
Recruiting
100 enrolled
Jazz Pharmaceuticals
Jazz Pharmaceuticals Research UK Limited · collab
NaSingle-groupOpen-labelTreatment
Summary
Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or Tuberous sclerosis complex (TSC) in patients 1 year of age and older. This study will assess the efficacy and safety of CBD-OS in participants aged 12 to 75 years for the treatment of focal-onset seizures (FOS).
Timeline
- Start
- 2025-11-26
- Primary completion
- 2027-11-29
- Completion
- 2027-11-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabidiol | Other / unclassified | — | — |